The objective of this paper is to introduce the methodology of economic analysis in health care, and its application to the measurement of the efficiency analysis of prostate cancer treatment. We presented the methodology of economic analysis. To review its application in prostate cancer treatment, we performed a bibliographic search in the main biomedical databases (February 1988 -January 2001 to identify economic evaluation studies that compared both costs and effects of prostate cancer treatments. The lack of economic studies for localized prostate cancer and the diversity of treatments for advanced prostate cancer make it difficult to make comparisons across studies and to make therapeutic recommendations. Prostate Cancer and Prostatic Diseases (2001) 4, 217-220.
Introduction
Prostate cancer is one of the leading causes of death by cancer in males in industrialized countries. Mortality rates by this cause vary between three cases per 1000 population/year in Japan and 22 cases per 1000 population/year in Norway. 1 The aging trend of the population, disease staging, and the long-term evolution of localized prostate cancers make the clinical management of the disease a public health dilemma for policy makers.
Once cancer is detected, decisions arise over the choice of the best therapeutic approach due to the long-term evolution of the tumor and the lack of evidence of how the different therapies might affect the patient's survival. Several strategies have been proposed, ranging from watchful observation to radical prostatectomy, including among others hormonotherapy, chemotherapy, or radiotherapy, each one with a different effectiveness, safety, and cost profiles.
In fact, prostate cancer treatment has an important cost for the health care system. Taplin et al estimated the average total cost of prostate cancer treatment including initial care in the first 6 months, continuing medical care during 3 months and terminal care in the last 6 months of life of $260 20 (1992 US dollars). 2 ECRI researchers estimated an average net cost -charge for care of agematched males with and without prostate cancer -of $137 90 (1994 US dollars). 3 Finally, in Canada the clinical burden of prostate cancer has been forecasted for the cohort of 5.8 million Canadian men between 40 and 80 y old in 1997. For those men, prostate cancer would be diagnosed in an estimated 701 491 men (12.1%) over their lifetime, with direct medical costs of $9.76 billion, or $3.89 billion when discounted 5% annually. 4 It is in this context of uncertainty about prostate cancer treatment effectiveness and efficiency in which important questions arise such as: Do we have an efficient alternative for prostate cancer treatment? Can we prescribe an effective therapy for it? Could the efficiency of the treatment be measured without efficacy or effectiveness data or hard outcomes? Which methods could be used? The objective of this paper is to introduce the methodology of economic analysis, and its application to the efficiency analysis of prostate cancer treatment.
Materials and methods
The basic tasks of any economic analysis in health care are to identify, measure, value and compare the costs and effects of the different alternatives under consideration.
The information provided by economic analysis has to be valued in addition to other types of assessments measuring the impact of using a specific health service either in terms of efficacy, safety, effectiveness, equity, or ethical implications. Costs and health outcomes are thus compared across different clinical management strategies. It is for this reasoning that economic assessment methods aim at answering specific efficiency questions. One could find excellent books of economic analysis in health care, 5, 6 and even some reviews with its application to prostate cancer, 7, 8 and here we present the most important points and some examples for the assessment of prostate cancer treatments.
The most widely used techniques in the economic assessment of health care services are: cost-analysis, cost-minimization analysis, cost-benefit analysis, costeffectiveness analysis, cost-efficacy analysis -or clinicaleconomic trials -and cost-utility analysis.
The first step to carry out an economic analysis is to agree on the perspective of analysis and the time horizon for follow-up. Perspective of analysis refers to the point of view from which the analysis is made: society, payer, provider, patient, etc. Time horizon is the period of time established in the study to value costs and consequences. In prostate cancer treatment, it could be interesting to set the society and the patient perspective, in order to take into account the effects of treatments in terms of quality of life, and to establish a time horizon long enough to reflect short and long-term effects of therapies.
The next step is to establish which sort of costs should be considered and which, if any, should not. A distinction should be made between direct, indirect and intangible costs. Direct costs refer to the monetary value of changes in resource use attributable to the prostate cancer treatment under assessment, and could be either medical or non-medical. It might include the cost of prostate cancer therapies, pharmacy costs, hospital costs, treatment of side effects, physician fees, or transport costs, among others.
Indirect costs, also called labor costs, reflect the monetary value of productivity losses by patients and their families as a result of being treated for prostate cancer. Intangible costs such as pain, suffering, and anxiety are the most difficult to define and estimate in economic measures, and no agreement exists on the method to value them. However, one might choose to take them into account qualitatively in order to select between alternatives.
The health effects to be considered can include changes in mortality, morbidity or quality of life as a result of prostate cancer treatment. Changes in mortality might be assessed as the number of lives saved, in-hospital mortality, long-term survival, or changes in life expectancy. By combining the change in length and quality of life, one can derive changes in quality-adjusted life years (QALYs).
Utility analysis considers alongside a well-defined health outcome measure, the quantitative value placed by individuals to this outcome. Several techniques have been proposed to elicit patients' preferences and to measure utilities, such as time trade-off or standard gamble. The application of utility assessment methods and measures remains controversial because there is no gold standard and their results may be difficult to interpret, to apply, and to generalize. Furthermore, factors such as timing, framing effects, method of eliciting preferences or the health context can affect utility values obtained. Nevertheless, prostate cancer treatment could be an interesting area to use utility measurement, since treatment could produce important adverse effects, resulting in different quality of life for patients and lead to cost variations. 
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Results
We performed a bibliographic search in the biomedical databases MEDLINE, HealthSTAR, Cancerlit, The Cochrane Library, and NEED (February 1988 -January 2001), with descriptors related to prostatic neoplasms, treatment, and economic analysis. We identified four economic evaluation studies that compared both costs and effects of different treatments for advanced prostate cancer. 9 -16 We did not find studies related to the treatment of localized prostate cancer. The results of the review are presented in Table 1 . As can be seen, the methodological characteristics varied across studies, as well as the alternatives compared, they are different in all the studies. The economic evaluation techniques used were costeffectiveness analysis 9, 15, 16 and cost-utility analysis. 10 -14 Outcome measures used were monetary units per years of life gained or per month of survival in the case of costeffectiveness analysis, 9, 15, 16 and monetary units per quality adjusted life years (QALY) in the case of cost-utility analysis 10 -14 (Tables 1 and 2 ). Effectiveness measurements came from randomized controlled trials, although the effect size was not always explicit.
The lack of economic studies for localized prostate cancer, and the diversity of treatments for advanced prostate cancer made the comparison of results difficult. Despite that statement, some conclusions can be remarked about advanced prostate cancer treatment, as can be seen in Table 3 . But, in general terms, it seems that economic findings clearly depend on clinical findings, ie on the treatment alternatives compared in the clinical trials and their relative effectiveness.
Discussion
The review of economic studies showed differences in study design along with the variability between the values of the different parameters, and the assumptions made by the researchers. The lack of economic studies for localized prostate cancer and the diversity of treatments for advanced prostate cancer make it difficult to make comparisons across studies and to make therapeutic recommendations.
The relevance of economic analysis must be based on the development and implementation of a methodological framework that guarantees the validity, reliability, reproducibility, comparability, quality and interpretation of the results of the analysis across similar health care contexts. Standards for economic analysis should make the results of analysis relevant and credible for policymaking, depending upon the perspective of analysis. In general terms, the usefulness of economic analysis of health services, and of cancer treatments in particular, is not in doubt. It could be used to define cost-effective alternatives, to value the costs of alternatives and, indeed, to make assumptions when randomized controlled trial data are lacking. 17 For men who accept it, orchiectomy is likely to be the most cost-effective androgen suppression strategy. Combined androgen blockade is the least economically attractive option, yielding small health benefits at relatively high costs Bloomfield et al, 1998 10 The use of mitoxantrone and prednisone does not incur in any additional cost over the use of prednisone alone, due to its best effectiveness require fewer hospital admissions Bennett et al 1996 11 Total androgen blockade improves survival and has maximal benefit in minimal disease patients. Although Hillner, 1996 12 orchiectomy is cheaper than LhRH treatment, total androgen blockade has an incremental costHillner et al, 1995 Economic assessment studies that compare different treatment alternatives available based on high quality evidence are highly recommended. The methodological strength in the application of economic assessment techniques is essential to guarantee the studies replicability, as is the use of appropriate clinical outcome measures from randomized controlled trials or meta-analysis of randomized controlled trials. Particularly in this case, in which adverse effects could be important (ie incontinence or impotence), it would be very interesting to carry out costutility analyses that valued for different ages, risk assessment of death, adverse effects, and benefits (in terms of survival) of the different treatment options for prostate cancer. 18 
Conclusions
In this clinical condition, there is no randomized controlled trial that demonstrates the superiority of any alternative in the treatment of localized prostate cancer in terms of survival or quality of life-adjusted years. On the other hand, some therapeutic alternatives have been shown in controlled trials to be effective in survival for men with metastatic prostate cancer. In this uncertain framework, treatment strategies could be based in clinical decisions, taking into account the importance of patients' preferences, trying to offer them minimal risk treatments and the best quality of life.
